76 pending office actions • 19 clients
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 19247822 | Untitled | Chugai Seiyaku Kabushiki Kaisha | COLEMAN, BRENDA LIBBY | 1624 | Non-Final OA | |
| 19104909 | INFUSION SITE FAILURE DETECTION | Eli Lilly And Company | SHELDEN, BION A | 3685 | Non-Final OA | Feb 19, 2025 |
| 18745729 | ANTI-NECTIN-4-ANTIBODIES AND USES THEREOF | Centre National De La Recherche Scientifique - Cnrs - | AEDER, SEAN E | 1642 | Non-Final OA | Jun 17, 2024 |
| 18713758 | SYSTEMS AND METHODS FOR IDENTIFYING SUBJECTS FOR CLINICAL TRIALS | Eli Lilly And Company | HEIN, DEVIN C | 3686 | Non-Final OA | May 28, 2024 |
| 18598084 | METHODS AND APPARATUSES FOR DETECTING ANOMALIES WHEN FILLING A CONTAINER WITH FLUID | Eli Lilly And Company | KOPPOLU, VAISALI RAO | 2664 | Non-Final OA | Mar 07, 2024 |
| 18597108 | METHODS FOR THE PREPARATION AND DOSE REGIMENS FOR USE OF SSTR4 AGONISTS AND SALTS THEREOF | Eli Lilly And Company | TAO, BIN | 1625 | Non-Final OA | Mar 06, 2024 |
| 18686475 | SYSTEMS AND METHODS FOR SENSING DEFECATION EVENTS | Eli Lilly And Company | OKONAK, ELIZABETH LOUISE | 3792 | Non-Final OA | Feb 26, 2024 |
| 18293823 | COMPOUNDS THAT INHIBIT PI3K ISOFORM ALPHA AND METHODS FOR TREATING CANCER | Scorpion Therapeutics, Inc. | HEITMEIER, KENDALL NICOLE | 1621 | Non-Final OA | Jan 31, 2024 |
| 18293978 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. | VALLE, ERNESTO | 1623 | Non-Final OA | Jan 31, 2024 |
| 18292486 | Treatment of Hand Eczema with Baricitinib | Eli Lilly And Company | OTTON, ALICIA L | 1699 | Non-Final OA | Jan 26, 2024 |
| 18568899 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | Scorpion Therapeutics, Inc. | CHONG, YONG SOO | 1623 | Non-Final OA | Dec 11, 2023 |
| 18567814 | 2019 NOVEL CORONAVIRUS ANTIBODY-CONTAINING PHARMACEUTICAL FORMULATIONS | Eli Lilly And Company | WANG, RUIXUE | 1672 | Non-Final OA | Dec 07, 2023 |
| 18523645 | THERAPEUTIC USES OF DULAGLUTIDE | Eli Lilly And Company | BEANE, RANDALL L | 1654 | Final Rejection | Nov 29, 2023 |
| 18501175 | AHR AGONISTS | Eli Lilly And Company | COPPINS, JANET L | 1628 | Non-Final OA | Nov 03, 2023 |
| 18555467 | COCRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR | Loxo Oncology, Inc. | RAHMANI, NILOOFAR | 1691 | Non-Final OA | Oct 13, 2023 |
| 18479828 | GENE THERAPY FOR TREM2-ASSOCIATED DISEASES AND DISORDERS | Eli Lilly And Company | HUMPHRIES, NICHOLAS ADAM | 1631 | Non-Final OA | Oct 03, 2023 |
| 18552897 | TABLET DISPENSER | Eli Lilly And Company | RANDALL, JR., KELVIN L | 3651 | Final Rejection | Sep 28, 2023 |
| 18467957 | ANTI-HUMAN LAIR1 ANTIBODIES | Trex Bio, Inc. | PRIEST, JESSICA MARIE | 1642 | Non-Final OA | Sep 15, 2023 |
| 18550214 | ANTI-N3pGlu AMYLOID BETA ANTIBODIES AND USES THEREOF | Eli Lilly And Company | BALLARD, KIMBERLY | 1675 | Non-Final OA | Sep 12, 2023 |
| 18549803 | ANTI-AMYLOID BETA ANTIBODIES AND USES THEREOF | Eli Lilly And Company | WEIDNER, ADAM M | 1675 | Non-Final OA | Sep 08, 2023 |
| 18549546 | USE OF MEVIDALEN AND OTHER D1 POSITIVE ALLOSTERIC MODULATORS IN THE TREATMENT OF HALLUCINATIONS AND DEMENTIA-RELATED PSYCHOSIS | Eli Lilly And Company | PECKHAM, RICHARD GRANT | 1627 | Non-Final OA | Sep 07, 2023 |
| 18547460 | SELF-ASPIRATING SYRINGE SYSTEMS, CARTRIDGES, AND METHODS | Eli Lilly And Company | AHMED, TASNIM M | 3783 | Non-Final OA | Aug 22, 2023 |
| 18366061 | TRANSFERRIN RECEPTOR BINDING PROTEINS AND CONJUGATES | Eli Lilly And Company | TAYLOR, LIA ELAN | 1641 | Non-Final OA | Aug 07, 2023 |
| 18262874 | METHODS AND APPARATUS FOR INCREMENTAL LEARNING USING STORED FEATURES | Eli Lilly And Company | BROUGHTON, KATHLEEN M | 2661 | Final Rejection | Jul 25, 2023 |
| 18262010 | STATUS SENSING SYSTEMS FOR CONNECTED INJECTION DEVICE | Eli Lilly And Company | DESANTO, MATTHEW F | 3700 | Non-Final OA | Jul 18, 2023 |
| 18260125 | ANTI-N3pGlu AMYLOID BETA ANTIBODIES AND USES THEREOF | Eli Lilly And Company | HOPKINS, SAMANTHA LAKE | 1641 | Non-Final OA | Jun 30, 2023 |
| 18343326 | KRAS Gl2C INHIBITORS | Eli Lilly And Company | YOO, SUN JAE | 1621 | Non-Final OA | Jun 28, 2023 |
| 18259500 | HALF-LIFE EXTENDING MOIETIES AND METHODS OF USING THE SAME | Eli Lilly And Company | KATAKAM, SUDHAKAR | 1658 | Non-Final OA | Jun 27, 2023 |
| 18257487 | FLUID DELIVERY SYSTEM WITH NEEDLE ASSEMBLY | Eli Lilly And Company | THOMAN, EVELYN ANNE | 3783 | Non-Final OA | Jun 14, 2023 |
| 18257506 | FLUID DELIVERY SYSTEM WITH NEEDLE ASSEMBLY | Eli Lilly And Company | STIGELL, THEODORE J | 3783 | Non-Final OA | Jun 14, 2023 |
| 18254270 | MEDICINE FOR ALLEVIATING NEUROPATHIC PAIN | Asahi Kasei Pharma Corporation | ROBINSON, MIKHAIL O'DONNEL | 1627 | Non-Final OA | May 24, 2023 |
| 18253541 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. | BAUER, NICOLA MARIA | 1621 | Non-Final OA | May 18, 2023 |
| 18314661 | CELL SPECIFIC GENE THERAPY DELIVERY COMPOSITIONS AND METHODS FOR TREATING HEARING LOSS | Akouos, Inc. | CHONG, KIMBERLY | 1636 | Non-Final OA | May 09, 2023 |
| 18314671 | CELL SPECIFIC GENE THERAPY DELIVERY COMPOSITIONS AND METHODS FOR TREATING HEARING LOSS | Akouos, Inc. | PRONZATI, GINA | 1633 | Non-Final OA | May 09, 2023 |
| 18252228 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. | AULAKH, CHARANJIT | 1621 | Non-Final OA | May 09, 2023 |
| 18143902 | VARIANT ADENO-ASSOCIATED VIRUS (AAV) CAPSID POLYPEPTIDES AND GENE THERAPEUTICS THEREOF FOR TREATMENT OF HEARING LOSS | Eli Lilly And Company | SHIBUYA, MARK LANCE | 1631 | Non-Final OA | May 05, 2023 |
| 18031494 | ASSAY FOR MEASURING POTENCY OF GENE THERAPY DRUG PRODUCT | Prevail Therapeutics, Inc. | PARKIN, JEFFREY S | 1671 | Non-Final OA | Apr 12, 2023 |
| 18247198 | METHODS FOR REDUCING HOST CELL PROTEIN CONTENT IN ANTIBODY PURIFICATION PROCESSES AND ANTIBODY COMPOSITIONS HAVING REDUCED HOST CELL PROTEIN CONTENT | Eli Lilly And Company | SZPERKA, MICHAEL EDWARD | 1641 | Non-Final OA | Mar 29, 2023 |
| 18245425 | ORAL DRUG DELIVERY DEVICE WITH EXPANDING BAND | Eli Lilly And Company | TRUONG, QUANGLONG N | 1615 | Non-Final OA | Mar 15, 2023 |
| 18044618 | DEVICES AND PROCESSES FOR DELIVERY OF THERAPEUTIC FLUIDS | Eli Lilly And Company | DARB, HAMZA A. | 3783 | Non-Final OA | Mar 09, 2023 |
| 18044504 | Therapeutic Antibody Formulations | Eli Lilly And Company | NOAKES, SUZANNE MARIE | 1656 | Non-Final OA | Mar 08, 2023 |
| 18043971 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | Loxo Oncology, Inc. | SEAMAN, D MARGARET M | 1625 | Non-Final OA | Mar 03, 2023 |
| 18176844 | THERAPEUTIC ANTIBODY FORMULATION | Eli Lilly And Company | KIM, YUNSOO | 1641 | Non-Final OA | Mar 01, 2023 |
| 18041898 | METHODS AND APPARATUS FOR DISPLAYING GLUCOSE DATA | Eli Lilly And Company | HALPRIN, MOLLY SARA | 3791 | Final Rejection | Feb 16, 2023 |
| 18041617 | OSIMERTINIB AND SELPERCATINIB COMBINATIONS FOR THE TREATMENT OF EGFR- AND RET-ASSOCIATED CANCERS | Loxo Oncology, Inc. | BURKETT, DANIEL JOHN | 1624 | Non-Final OA | Feb 14, 2023 |
| 18168426 | COMPOSITIONS AND METHODS FOR THE TARGETING OF SOD1 | Scribe Therapeutics Inc. | BATES, KEENAN ALEXANDER | 1631 | Non-Final OA | Feb 13, 2023 |
| 18041199 | GENE THERAPIES FOR NEURODEGENERATIVE DISORDERS | Prevail Therapeutics, Inc. | LARA, CAROLINE MONSERRAT | 1633 | Non-Final OA | Feb 09, 2023 |
| 18006593 | PHYSIOLOGICAL DATA MONITORING SYSTEM | Eli Lilly And Company | SWEARINGEN, JEFFREY R | 2445 | Final Rejection | Jan 24, 2023 |
| 18005245 | LOW DOSE REGIMEN AND FORMULATION OF A 5-METHYL-1,2,4-OXADIAZOL-3-YL COMPOUND | Eli Lilly And Company | MOU, LIYUAN | 1628 | Final Rejection | Jan 12, 2023 |
| 18149982 | METHODS OF USING AND COMPOSITIONS CONTAINING DULAGLUTIDE | Eli Lilly And Company | SABILA, MERCY HELLEN | 1654 | Non-Final OA | Jan 04, 2023 |
| 18011965 | PREVENTION OF AXONAL DAMAGE USING ANTIBODY BINDING TO AMYLOID BETA 1-42 | Eli Lilly And Company | WANG, CHANG YU | 1675 | Non-Final OA | Dec 21, 2022 |
| 17998486 | COMPOSITIONS AND METHODS FOR TREATING GJB2-ASSOCIATED HEARING LOSS | Akouos, Inc. | MCLEOD, AFRICA MHAIRIE | 1635 | Non-Final OA | Nov 10, 2022 |
| 17920118 | PAN-ELR+ CXC CHEMOKINE ANTIBODIES FOR THE TREATMENT OF RESPIRATORY DISEASE | Eli Lilly And Company | SAOUD, CHRISTINE J | 1645 | Non-Final OA | Oct 20, 2022 |
| 17969043 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Morphic Therapeutic, Inc. | OH, TAYLOR V | 1625 | Non-Final OA | Oct 19, 2022 |
| 17996028 | CRYSTALLINE RET INHIBITOR | Loxo Oncology, Inc. | MARTIN, KEVIN STEPHEN | 1624 | Final Rejection | Oct 12, 2022 |
| 17932798 | COMPOSITIONS AND METHODS FOR THE TARGETING OF C9orf72 | Scribe Therapeutics Inc. | MCLEOD, AFRICA MHAIRIE | 1635 | Non-Final OA | Sep 16, 2022 |
| 17906580 | FARNESOID X RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASE | Eli Lilly And Company | BURKETT, DANIEL JOHN | 1624 | Final Rejection | Sep 16, 2022 |
| 17883072 | Anti-CGRP Antibody Formulation | Eli Lilly And Company | WANG, CHANG YU | 1675 | Final Rejection | Aug 08, 2022 |
| 17779463 | MEDICATION DELIVERY DEVICE WITH SENSING SYSTEM | Eli Lilly And Company | WITTLIFF, KATERINA ANNA | 3783 | Non-Final OA | May 24, 2022 |
| 17743864 | Treatment of Genital Psoriasis | Eli Lilly And Company | JIANG, DONG | 1674 | Non-Final OA | May 13, 2022 |
| 17768706 | COMPOUNDS WITH IMPROVED PHARMACOKINETICS FOR IMAGING AND THERAPY OF CANCER | Technische Universität München | PERREIRA, MELISSA JEAN | 1618 | Non-Final OA | Apr 13, 2022 |
| 17689286 | Methods of treating cancer using a combination of SERD Dosing Regimens | Eli Lilly And Company | ADLAM, CHANTAL PETA-GAYE | 1622 | Non-Final OA | Mar 08, 2022 |
| 17641426 | COMPOSITIONS AND METHODS FOR THE TARGETING OF SOD1 | Scribe Therapeutics Inc. | RYAN, DOUGLAS CHARLES | 1635 | Non-Final OA | Mar 08, 2022 |
| 17639862 | TREATMENT OF LIVER DISEASE OR DISORDER COMPRISING ACTRII RECEPTOR ANTAGONISTS | Novartis AG | SAOUD, CHRISTINE J | 1645 | Final Rejection | Mar 02, 2022 |
| 17639794 | PROTEINS COMPRISING T-CELL RECEPTOR CONSTANT DOMAINS | The University of North Carolina at Chapel Hill | PETERS, ALEC JON | 1641 | Final Rejection | Mar 02, 2022 |
| 17633631 | METHODS OF MAKING INCRETIN ANALOGS | Eli Lilly And Company | REYNOLDS, FRED H | 1658 | Final Rejection | Feb 08, 2022 |
| 17625180 | METHOD AND SYSTEM FOR DETERMINING GLUCOSE CHANGE IN A SUBJECT | Eli Lilly And Company | SANFORD, DIANA PATRICIA | 1687 | Final Rejection | Jan 06, 2022 |
| 17554713 | Anti-CGRP Antibody Formulation | Eli Lilly And Company | BORGEEST, CHRISTINA M | 1675 | Non-Final OA | Dec 17, 2021 |
| 17619289 | SYSTEMS AND METHODS FOR DETECTING MISSED BOLUS DOSES | Eli Lilly And Company | PLAYER, ROBERT AUSTIN | 1686 | Final Rejection | Dec 15, 2021 |
| 17535059 | COMPOUNDS AND METHODS TARGETING HUMAN TAU | Eli Lilly And Company | BALLARD, KIMBERLY | 1675 | Non-Final OA | Nov 24, 2021 |
| 17439066 | INTEGRATED INSERTER/APPLICATOR FOR A DRUG DELIVERY SYSTEM PROVIDING MULTIPLE WEAR CONFIGURATIONS | Eli Lilly And Company | THOMAN, EVELYN ANNE | 3783 | Non-Final OA | Sep 14, 2021 |
| 17462872 | ENDOCRINE THERAPY AND ABEMACICLIB COMBINATION FOR THE ADJUVANT TREATMENT OF NODE-POSITIVE, EARLY STAGE, HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE BREAST CANCER | Eli Lilly And Company | SEITZ, ANTHONY JOSEPH | 1629 | Final Rejection | Aug 31, 2021 |
| 17433795 | MEDICATION DELIVERY DEVICE WITH SENSING SYSTEM | Eli Lilly And Company | DARB, HAMZA A. | 3783 | Non-Final OA | Aug 25, 2021 |
| 17354195 | Antibodies that bind TGF-Alpha and Epiregulin for use in the treatment of pain | Eli Lilly And Company | ALLEN, MARIANNE P | 1647 | Final Rejection | Jun 22, 2021 |
| 17211163 | COMBINATION THERAPY | Eli Lilly And Company | BALLARD, KIMBERLY | 1675 | Non-Final OA | Mar 24, 2021 |
| 17270331 | Acylated Calcitonin Mimetics | Keybioscience AG | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | Final Rejection | Feb 22, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial